Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.
Sumanta K. Pal, MD
Advertisement
Articles by Sumanta K. Pal, MD
Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.
Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.
Sumanta Kumar Pal, MD, FASCO, discusses the genomic activity of adjuvant atezolizumab vs placebo in patients with high-risk resected RCC.
Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr Pal on the Rationale for Evaluating Atezolizumab in High-Risk Localized RCCPublished: September 18th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5